Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines

Investigational New Drugs

Volumn 18, Issue 2, 2000, Pages 139-148

  Taron, Miquel ^a   Plasencia, Carmen ^a   Abad, Albert ^a   Martin, Cristina ^a   Guillot, Mónica ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Bleomycin; Cell cycle; Docetaxel; Etoposide; Synergism; Topotecan

Indexed keywords

BLEOMYCIN; DOCETAXEL; ETOPOSIDE; PROTEIN P53; TOPOTECAN;

ARTICLE; BREAST ADENOCARCINOMA; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; LUNG NON SMALL CELL CANCER; METHODOLOGY; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0034060908     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006325929424     Document Type: Article

References (53)

1. Dancey J, Eisenhauer E: Current perspectives on camptothecins in cancer treatment (Editorial). Br J Cancer 74: 327-338, 1996
2. Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumour agents. J Natl Cancer Inst 85(4): 221-291, 1993
3. Li LH, Fraser TJ, Olin EJ, Bhuyan BK. Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643-2650, 1972
4. Johnson E, Fridborg H, Csóka K, Sundstrom C, Nygren P, Larsson R: Cytotoxic activity of Topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 76(2): 211-219, 1997
5. Holm E, Lovey JM, Kerrigan D, Pomier Y: Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and 11 in Chinese hamster DC3F cells. Cancer Res 49: 6365-6368, 1989
6. Burris HA, Hanauske, A, Johnson F, Marshall M, Khun J, Hilsenbeck SE, Von Hoff DD: Activity of topotecan, a new topoisomerase I inhibitor against human colony-forming units in vitro. J Natl Cancer Inst 84: 1816-1819, 1992
7. Perez-Soler R, Fosella F, Glisson B, Lee J, Murphy W, Shin D, Kemp BL, Lee JJ, Kave J, Robinson RA, Lippman SM, Kurie JM, Huber W, Raber MN, Hong WK: Phase 11 study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14: 503-513, 1996
8. Uckun FM, Stewart CF, Reaman G, Chelstrom LM, Jin J, Chandan-Langlie M, Waddick KG, White J, Evans WE: In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 85: 2817-282, 1995
9. Creemers GJ, Bolis G, Gore M, Scarfone G, Lacave AJ, Guastalla JP, Despax R: Topotecan an active drug in the second-line treatment of epithelial ovarian cancer: results of large European phase H study. J Clin Oncol 14: 3056-3061, 1996
10. Hsiang YH, Hertzberg F, Hecht S, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase 1. J Biol Chem 260: 14873-14878, 1985
11. Kaufmann S, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK: Cytotoxic, effects of Topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88 (11): 734-741, 1996
12. Hsiang YK, Lihon MG, Liu LF: Arrest of replication forks by drug-stabilized Topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989
13. D'Arpa P, Beardmore C, Liu LF: Involvement of nucleic acid synthesis in cell killing mechanisms of Topoisomerase Poisons. Cancer Res 50: 6919-6924, 1990
14. Champoux J: Evidence for a intermediate with a single-strand break in the reaction catalysed by DNA untwisting enzyme. Proc Natl Acad Sci (USA) 73: 384-391, 1976
15. Shinka BK: Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 49: 11-19, 1995
16. Goldwasser F, Shimizu T, Jackman J, Hoki Y, O'Connor PM, Kohn KW, Pommier Y: Correlation between S and G2 arrest and the cytotoxicity of Camptothecin in Human Colon Carcinoma Cells. Cancer Res 56: 4430-4037, 1996
17. Del Bino G, Skiersky TS, Darzynkiewiz Z: Diverse effects of camptothecin an inhibitor of topoisomerase I on the cell cycle (L210, MOLT4) and myelogenous (HL60, KGI) leukemic cells. Cancer Res 50: 2746-2750, 1990
18. Slichenmeyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as anticancer agents. J Natl Cancer Inst 85: 271-287, 1993
19. 1. Cancer Res 52: 1823-1829, 1992
20. Shao R, Cao C, Shimizu T, O'Connor PM, Kohn KW, Pomier Y: Abrogation of an S-phase checkpoint and potentiation of Camptothecin cytotoxicity by 7-Hydroxistausporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 57: 4029-4035, 1997
21. Barlogie B, Drewinko B: Cell cycle stage-dependent induction of G2-phase arrest by different antitumour agents. Eur J Cancer 14: 741-745, 1978
22. Stewart N, I-Ecks GE, Paraskevas F, Mowat M: Evidence for a second cell cycle block at G2/M by p53. Oncogene 10: 109-115, 1995
23. Skladanowski A, Larsen AK: Expression of a wild-type p53 increases Etoposide cytotoxicity in M1 myeloid leukemia cells by facilited G2 to M transition: implications for gene therapy. Cancer Res 57: 818-823, 1997
24. Lowe SW, Ruley BE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (6): 957-967, 1993
25. Fan S, Smith ML, Rivet DJ, Duba D, Zahn Q, Kohn KW Fornace AJ Jr, O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cis-platin and pentoxyfilline. Cancer Res 55: 1643-1648, 1995
26. Ferreira CG, Tolis, C, Giaccone G. p53 and chemosensitivity. Ann Oncol 10: 1011-1021, 1999
27. Sikic BI: Biochemichal and cellular determination of Bleomycin cytotoxicity. Cancer Surv 5: 81-96, 1988
28. Povirk LF, Wübker W, Köhnlein W, Hutchinson F: DNA double-strand breaks and alkali-labile bonds produced by Bleomycin. Nucleic Acid Res 4: 3573-3580, 1977
29. Poddevin B, Orlowsky S, Belehradek JJr, Mir LM: Very high cytotoxicity of Bleomycin introduced into the cytosol of cells in culture. Biochem Pharmacol 42(5): 67-75, 1991
30. Desai LS, Khriskan A, Foley GE: Effects of Bleomycin on cells in culture cytochemical study. Cancer 34: 1973-1977, 1974
31. Tobey RA: Arrest of Chinese hamster cells in G2 following treatment with the anti-tumor drug Bleomycin. J Cell Physiol 76: 259-265, 1972
32. Green JL, De Carvalho K Wittes RE, Allegra CJ: Chemotherapy: the properties and uses of single agents. In: MacDonald JS, Haller DG, Mayer RJ (eds): Manual of Oncologic Therapeutics. (Third edition) JB Lippincott Company, Philadelphia, 1995, pp 105-106
33. Hill BT, Whelan RDK Shellard SA, McClean S, Hosking LK: Differential cytotoxic effects of Docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Inv New Drugs 12: 169-182, 1994
34. Kelland LR and Abel G: Comparative "in vitro" cytotoxicity of taxol and taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemoth Pharmacol 30: 444-450, 1992
35. Verweij J, Clavel M, Chevalier B: Placitaxel (Taxot) and Docetaxel (Taxotere): not simply two of a kind. Ann Oncol 5: 495-505, 1994
36. Bissery MC, Guenard D, Gueritte-Voegelein G, Lavelle F: Experimental antiturnour activity of Taxotere (RP 56976 NSC6288850), a taxol analogue. Cancer Res 5: 4845-4852, 1995
37. Riou JF, Naudin A, Lavelle F: Effects of Taxotere on murine and human tumor cell lines. Bioch Biophys Res Com 187(1): 164-170, 1992
38. Estey L, Adlakha RC, Hittleman WN, Zwelling LA: Cell cycle stage dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. Biochem 26: 4438-4444, 1987
39. Markovits J, Pomier Y, Kerrigan D, Covey JM, Tilchen EJ, Kohn KW: Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH3T3 fibroblasts and L1210 leukemia cells. Cancer Res 47: 2050-2055, 1987
40. Long BK Musial ST, Bratain MG: Single and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to Etoposide and Teniposide. Cancer Res 45: 3106-3112, 1985
41. Eijdems EVd-IM, de Haas M, Timmerman AJ, Van der Schans GP, Kamst E, de Nooij J, Astaldi-Riccotti GCB, Borst P, Baas F: Reduced topoisomerase H activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer 71: 40-47, 1995
42. Vindelov LL: Flow microfluorometric analysis of nuclear DNA in cells from solid tumour and cell suspensions. Virchows Arch B Cell Pathol 24: 227-242, 1977
43. Drewinko B, Green C, Loo TL: Combination chemotherapy in vitro with cisdichloroammineplatinum (II). Cancer Treat Rep 60(11): 1619-1625, 1976
44. McDonald AC, Brown R: Induction of p53-dependent and p53-independent cellular responses by topoisomerase-I inhibitors. Br J Cancer 78 (6): 745-751, 1998
45. Lowe SC: Clinical implications of p53-dependent apoptosis. In Educational Book of Am Soc Clin Oncol 41: 1, 1995
46. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991
47. Kaufmann SH: Antagonism between Camptothecin and Topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129-1136, 1991
48. Whitacre CM, Zborowska. E, Gordon NH, Mackayand W, Berger NA: Topotecan increases Topoisomerase IIα levels and sensitivity to treatment with etoposide, in schedule-dependent processes. Cancer Res 57: 1425-1428, 1997
49. Bonner JA, Kozelsky TF. The significance of the sequence administration of topotecan and etoposide: Cancer Chemother Pharmacol 39 (1-2): 109-112, 1996
50. Bertrand R, O'Connor PM, Kerrigan D, Pommier Y: Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT29 cells. Eur J Cancer 28: 743-748, 1992
51. Cheng MF, Chatterjee S, Berger NA: Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6: 269-279, 1994
52. Whal AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW, Galloway DA: Loss of normal p53 function confers sensitisation to Taxol by increasing G2/M arrest and apoptosis. Nature Med 2 (1): 72-79, 1996
53. Hennequin C, Giocanti N, Favaudon V: S-phase specificity of cell killing by Docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 71: 1194-1198, 1995